In an upcoming webinar, Novonesis will reveal new, unpublished data on the health benefits of human milk oligosaccharides (HMOs) for infant nutrition and other applications. The company has taken “significant steps” to uncover the bioactive compounds’ structural diversity and specific advantages in infant immunity, gut health and beyond. Ahead of the webinar, “HMOs and health benefits: From scientific insights to applications,” Nutrition Insight sits down with the expert speakers in the session, Yannik Schönknecht, senior scientific adviser at Novonesis and Dr. Stine Rikke Jensen, the company’s head of applied HMO Science and Innovation.
